Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway

BACKGROUND: Induction therapy for acute myeloid leukemia (AML) is an anthracycline-based chemotherapy regimen. However, many patients experience a relapse or exhibit refractory disease (R/R). There is an urgent need for more effective regimens to reverse anthracycline resistance in these patients. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hao, Liu, Yu-chen, Zhu, Cheng-ying, Yan, Fei, Wang, Meng-zhen, Chen, Xiao-su, Wang, Xiao-kai, Pang, Bao-xu, Li, Yong-hui, Liu, Dai-hong, Gao, Chun-ji, Liu, Shu-jun, Dou, Li-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724824/
https://www.ncbi.nlm.nih.gov/pubmed/33298132
http://dx.doi.org/10.1186/s13046-020-01792-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724824/
https://www.ncbi.nlm.nih.gov/pubmed/33298132
http://dx.doi.org/10.1186/s13046-020-01792-8

Ejemplares similares